BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 932 filers reported holding BAXTER INTL INC in Q1 2023. The put-call ratio across all filers is 0.56 and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $363,700 | +23.0% | 9,637 | +32.2% | 0.22% | +74.8% |
Q1 2023 | $295,682 | +7.1% | 7,290 | +34.6% | 0.12% | -3.9% |
Q4 2022 | $276,104 | -26.6% | 5,417 | +11.7% | 0.13% | +276.5% |
Q1 2022 | $376,000 | -89.1% | 4,849 | -87.9% | 0.03% | -88.8% |
Q4 2021 | $3,443,000 | -72.0% | 40,107 | -73.8% | 0.30% | -55.0% |
Q2 2021 | $12,306,000 | +556.7% | 152,872 | +587.9% | 0.67% | +250.5% |
Q1 2021 | $1,874,000 | -66.2% | 22,223 | -67.8% | 0.19% | -74.6% |
Q3 2020 | $5,550,000 | +79.8% | 69,016 | +87.0% | 0.76% | +114.5% |
Q4 2019 | $3,086,000 | +144.1% | 36,903 | +155.4% | 0.35% | +83.3% |
Q3 2019 | $1,264,000 | +53.8% | 14,447 | +43.0% | 0.19% | +67.0% |
Q1 2019 | $822,000 | – | 10,106 | – | 0.12% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |